Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Safety management of CAR-T cell therapy in DLBCL

Ulrich Jäger • 12 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma CAR-T

Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses the short and long-term safety of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL) and the guidelines used to prevent CRS and neurotoxicities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ulrich Jäger

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies 1:23
The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger • 7 Feb 2025
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia 1:32
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger • 7 Feb 2025
Working towards the harmonization of CAR-T registries 1:17
Working towards the harmonization of CAR-T registries
Ulrich Jäger • 7 Feb 2025
The potential role of the tumor microenvironment in CAR T-cell therapy 0:52
The potential role of the tumor microenvironment in CAR T-cell therapy
Ulrich Jäger • 7 Feb 2025

Related Videos

Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL 3:25
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL
Manali Kamdar • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals